Passage Bio shares are trading higher after Oppenheimer initiated its coverage on the stock with an Outperform rating and announced a price target of $30.

Benzinga Newsdesk www.benzinga.com Positive 94.7%

Neg 0% Neu 0% Pos 94.7%

Comments

No comments yet. Be the first!